What is Michelson Diagnostics?
Michelson Diagnostics Ltd is a prominent provider of Optical Coherence Tomography (OCT) skin imaging solutions, focusing on high-resolution imaging technology. Their primary product, VivoSight Dx Pro, is engineered to elevate clinical dermatology and skin research by offering rapid and precise monitoring of skin health. The company serves dermatologists, researchers, and medical clinics, aiming to make advanced imaging technology more accessible and user-friendly. Established in 2006, Michelson Diagnostics has garnered recognition in over 700 peer-reviewed publications for its pioneering contributions to dermatological imaging, positioning itself as a leader in the medical imaging sector.
How much funding has Michelson Diagnostics raised?
Michelson Diagnostics has raised a total of $7.1M across 2 funding rounds:
Series A
$3.3M
Series B
$3.8M
Series A (2014): $3.3M with participation from Catapult Venture Managers Ltd and Turner Investments
Series B (2015): $3.8M led by Turner Investments and Catapult Venture Managers Ltd
Key Investors in Michelson Diagnostics
Turner Investments
Turner Investments specializes in providing comprehensive financial research and insights aimed at helping investors make informed decisions. They conduct thorough analyses across various asset classes, including equities, fixed income, and alternative investments, utilizing both quantitative and qualitative methods.
Catapult Venture Managers Ltd
Catapult Ventures specializes in providing tailored investment solutions to meet the funding needs of entrepreneurs and business owners. The company focuses on unlocking potential and supporting clients in realizing their goals and ambitions.
What's next for Michelson Diagnostics?
With a substantial capital infusion, Michelson Diagnostics is poised for accelerated growth and technological advancement. The recent major strategic investment signals strong investor confidence in the company's innovative OCT technology and its potential to transform dermatological care. This backing will likely support the scaling of manufacturing operations, expansion into new global markets, and continued research and development efforts to enhance the capabilities of their imaging systems. The company's trajectory suggests a focus on solidifying its market leadership and exploring new applications for its advanced skin imaging solutions, potentially broadening its impact across various medical disciplines.
See full Michelson Diagnostics company page
